---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000049"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T22:21:51.500272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances

## Summary
- Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).
- Cash and marketable securities $349.0M as of June 30, 2023, down from $467.9M at Dec 31, 2022.
- BHV-7000 Kv7 activator showed CNS target engagement without somnolence; Phase 2/3 in epilepsy and bipolar disorder planned 2H 2023.
- FDA refused to file troriluzole NDA for SCA3; Biohaven plans Type A meeting to address FDA concerns.
- BHV-8000 (TYK2/JAK1) Phase 1 SAD dosed, well tolerated; Phase 2 in Parkinson's disease planned 2024.

## SEC filing metadata
- accession: 0001935979-23-000049
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/0001935979-23-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/bhvn-20230731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000049
- JSON: https://secwatch.observer/filing/0001935979-23-000049.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000049.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/0001935979-23-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.